Bausch Health (BHC) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Amneal Pharmaceuticals Gets US FDA Approvals for Alzheimer's, Oncology Treatments, Gastrointestinal Disease
MT NewswiresJan 23 09:31 ET
Bausch Health to Announce Fourth Quarter and Full Year 2024 Results on February 19, 2025
AccesswireJan 23 07:00 ET
Market Chatter: Bausch Health Swaps Out Advisers After Years of Debt, Sale Talks
Yahoo FinanceJan 22 17:23 ET
RBC on FDA's Third Tentative Approval For Rifaximin 550mg to Amneal Pharmaceuticals
MT NewswiresJan 17 13:03 ET
Bausch Health And Salix Pharmaceuticals Announced That CMS Selected XIFAXAN 550 Mg For Drug Price Negotiation Under Inflation Reduction Act, Effective 2027; XIFAXAN Approved For HE And IBS-D In Adults, Rated Grade I, A,1 By Liver Disease Associations
BenzingaJan 17 09:27 ET
Bausch Health Statement on Selection of XIFAXAN(R) (Rifaximin) for Inflation Reduction Act's Medicare Negotiation Program
AccesswireJan 17 09:25 ET

Comments

Stock Region

Jul 24, 2024 18:51

Health Company Responds To False Rumors Over Bankruptcy Consideration

Bausch Health Responds to Market Rumors.
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) recently found itself at the center of market rumors that suggested the company was considering bankruptcy or insolvency proceedings. These rumors originated from an article issued by Reorg®, citing unnamed sources. In response, Bausch Health has categorically denied these claims, emphasizing that they are unsubstantiated and without merit...

Mcsnacks H Tupack

Jul 24, 2024 12:16

Refutes claim

$Bausch Health (BHC.US)$ See you at 8.00.

2

Moomoo AI

Jun 22, 2024 08:31

Bausch Health's revenue growth is unimpressive due to its lack of profitability. The share price crash may be an over-reaction, but improvements in business fundamentals are needed before considering a purchase. The company's long-term performance is concerning, and clear growth indicators are required for share price stability.

Strong Week for Bausch Health Companies (NYSE:BHC) Shareholders Doesn't Alleviate Pain of Three-year Loss

2

Options Newsman

Apr 5, 2024 20:47

Columns Options Market Statistics: TSLA Shares Fall and Options Pop as Reports Suggest the Company Scraps Low-cost Car Plans

News Highlights
$Tesla (TSLA.US)$ shares fell by 3.63%, closing at $164.90. Its options trading volume was 3.83 million. Call contracts account for 48.3% of the total trading volume. The most traded calls are contracts of $170 strike price that expire on Apr. 5th. The total volume reaches 106,470 with an open interest of 29,026. The most traded puts are contracts of a $165 strike p...

45

24

48

Meltyy

Feb 21, 2024 21:25

Why Is Emergent BioSolutions (EBS) Stock Up 70% Today?

In today’s market, one of the biggest winners generating outsized interest is $Emergent BioSolutions (EBS.US)$ . This mid-cap biotech company remains a unique turnaround story for investors, and many appear to be placing their bets on this company to come out of the pile as a key winner. Indeed, EBS stock has surged over 70% higher on some intriguing news this afternoon.
The company’s turnaround efforts appear to be receiving a jolt today, wit...

8

1

BHC Bausch Health

Trade Overview

Capital Trend

News

Comments

Trending Stocks